Navigation Links
Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
Date:7/9/2008

BANNOCKBURN, Ill., July 10 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company today announced it has entered into an agreement with pharmexx to expand sales support activities in a number of countries in Western Europe. Terms of the agreement were not disclosed.

Viren Grover, Vice-Chairman of Pinnacle Biologics Inc. stated, "We are pleased to conclude this agreement with pharmexx, which allows us a cost effective way to support our sales and marketing activities for Ethyol (R) in key European markets where we believe there is upside potential."

Georg Nagl, CEO of pharmexx said, "pharmexx is delighted to be working with Pinnacle on their new venture in Europe. Our businesses are a good fit and provide an ideal win/win opportunity; we look forward to a long and successful relationship."

About Pinnacle Biologics

Founded in 2007 by former Abbott Laboratories executives Guillermo Herrera, Viren Grover, and James R. Miller, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billings and collections), pharmacovigilence, product safety, market research and administrative services.

Pinnacle holds executive offices in Bannockburn, Illinois, satellite offices in Rockville, Maryland, and Almere, The Netherlands. Further information is available at http://www.pinnaclebiologics.com

About pharmexx:

pharmexx is one of the leading contract sales organizations (CSO) world-wide. pharmexx provides pharmaceutical and biotechnology companies with creative marketing and sales solutions, and high quality sales teams.

pharmexx has developed into Europe's number one CSO operating in 53 countries and employing over 6,000 medical sales representatives and covering more than 50,000 physicians and pharmacists every day. http://www.pharmexx.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1 (240) 372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
2. Pinnacle Biologics Announces Contract With Chiltern
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
5. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
8. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016  Why are two uber-successful ... Lorna Weir launching a new venture—yet going ... they believe that truly helping clients raise the value ... now demands a different type of collaboration. ... the pharmaceutical, biotechnology and medical device sectors. Elevate specializes ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
(Date:5/3/2016)... India , May 3, 2016 /PRNewswire/ ... (DNA Chip (Genomics, Drug Discovery, Gene Expression) ... End user (Academics Institutes, Diagnostics Centers), Fabrication ... published by MarketsandMarkets, the market is expected ... from USD 7.63 Billion in 2015, growing ...
(Date:5/3/2016)... ... May 03, 2016 , ... Kerafast Inc., developers ... from laboratories across the globe, today announced the availability of a Zika virus ... research toward treatment and prevention measures for the Zika virus, the virus’s geographical ...
Breaking Biology Technology:
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
Breaking Biology News(10 mins):